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by Dawn Chalaire and Beth W. Allen

ike all cancers, renal cell carcinoma grows and
spreads through subterfuge-using the body
own cells against it. Now researchers at The
University of Texas M. D. Anderson Cancer
Center are gi,ving the disease a taste of its own
medicine by developing vaccines from tumor cells to treat
the disease.
Clinical researcher Robert J Amato, D. 0., who leads
the renal cell program in the Department of Genitourinary
Medical Oncology, says the therapy is an especially good fit:
"It is novel, " he said, "and it makes sense in this cancer
because this is an immunogenic tumor. "

s

FACTS
Renal Cell Carcinoma
- - - - - - - - - - - - - Medical lberapy Approaches
t Adaptive immunotherapy
- Kidney cancer will
be diagnosed in about
17,800 American men
this year.
- It is the eighth most
commonly diagnosed
cancer in men.
SOURCE: American Cancer Society 1999

Therapy with targeted receptors
Angiogenesis inhibition
Novel agents
lmmunotherapy
.
Correlation of genetic expressmn
and clinical outcome
t Therapy based on uncommon
histology

t
t
t
t
t

But the vaccine approa h i ju t
one part of a five-track pr gram t
broaden therapeuti option for
patien ts with renal cell car inoma.
Jump-started in 1998 by Dr. Amat
the program is d riven by an 11member multidisciplinary, orkin
group that in the last year h
increased fivefold th num r f
renal cell carcinoma tri
conducted at M. D. And
renal cell working group con i
members from the departm n
genitourinary medical one I
carcinogenesis, molecular on ol
n euro-oncology, pathology, immunology, and blood and marr w
transplantation.
(Continued on next

page)

Also in this issue
Page 2: Protocols
See M. D . Anderson 's list of clinical
trials for treated and untreated
patients.

Page 6: Nephrectomy
A prospective, randomized trial is
u nder way to determine whether
surgery should precede or follow
other therapy.

New Options Expand Renal
Cancer Therapy Program
(Continued from page 1)

The outlook for patients with
renal cell carcinoma has long been
grim. Renal cell carcinoma is resistant to chemotherapy, and radical
nephrectomy is the standard tre~tm nt for localized disease. Despite
impro ements in surgical techniques
and th u of such immunotherapy
·
kin-2 and alpha
ple with renal
ithin one year
ne third of
ave metastases
ti tics, Dr.
ymore
nal cell
needed.

Dr. Robert Amato wads the I I-member
multidisciplinary renal cell carcinoma
working group.

In addition to the adaptive
immunotherapy protocols featuring
vaccines, other initiatives include
using anti-epidermal growth factor
receptor (EGFr) antibody C225,
inhibiting tumor growth by antiangiogenesis, employing novel agents
never used in phase II renal cell
trials, and using immunotherapy.
The newest area of pre clinical
studies in renal cell carcinoma
involves genetic expression analysis.
Scientists at M. D. Anderson are

----+--

Renal Cell Carcinoma
Trials Offer Therapies
for Treated and
Untreated Patients
Clinical trials currently in progress at
The University of Texas M. D. Anderson
Cancer Center include the followi ng for
patients with renal cancer.
• Phase II trial of effect of radical nephrectomy on tumor response to systemic
biologic therapy in patients with metastatic renal cell carcinoma (U RL98-140) .
Physician: Christopher G. Wood, M.D.
Participants in this study must be
older than 18 years of age, have a
normally functioning contralateral
kidney, and be able to undergo surgery
within two weeks of randomization .
Metastasis must have a soft tissue
component (if disease has metastasized
to the bone) or foci that are bidimensionally quantifiable on magnetic
resonance imaging. Pulmonary nodules
must have indicator lesions of> 1 cm ,
and hepatic indicator lesions must be
> 1.5 cm. Zubrod performance status
must be~ 2. Patients must meet the
following blood count requirements:
2 /
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hemoglobin, ~ 9.5 g/dl; absolute
neutrophil count, > 1500/mm 3; platelet
count, > 100,000/mm 3; bilirubin, ~ 1.5
mg/di. The transaminase level must be
less than or equal to two times the
upper limit of normal. Exclusion criteria
include evidence of congestive heart
failure, symptoms of coronary artery
disease, serious cardiac arrhythmia,
previous myocardial infarction, and
evidence of central nervous system
metastases. Patients will also undergo
systemic interleukin-2-based therapy.
• Phase II trial of active specific immunotherapy in patients with renal cell
carcinoma using autologous tumorderived heat-shock protein-peptide
complex with or without subcutaneous
interleukin-2 and integrated surgery
(DM99-006). Physician: Robert J.
Amato, D.D.
A minimum of 2 gm of non necrotic
renal cell carcinoma is required from
participants for vaccine preparation.
The primary tumor must be intact with
clinical evidence of metastatic disease.
Patients must be at least 16 years old
and have a Zubrod performance status
of~ 2. Required blood counts are as
follows: absolute neutrophil count,
> 1500/mm 3; platelet count, > 100,000/

mm 3; bilirubin , ~ 1.5 mg/di; and serum
creatinine, ~ 2 mg/di. SGPT must be
less than or equal to four times the
upper limit of normal. Prospective
patients must not have undergone prior
chemotherapy or immunotherapy. Other
exclusion criteria include brain metastases,
serious intercurrent medical illnesses,
or a history of prior or secondary
immunodeficiency.
• A randomized study of surgery versus
stereotactic radiosurgery in the treatment of single brain metastases among
patients with known or unknown primary
cancers (NS97-199). Physician:
Frederick Lang, M.D.
To be eligible for this study, patients
with renal cell cancer or other tumors
must have been diagnosed with single
brain metastases as determined by
magnetic resonance imaging within two
weeks of randomization . Tumors must
have a diameter~ 3 cm and be amenable to surgery and radiosurgery as
assessed by the neurosurgeon and
radiation oncologist. A Karnofsky score
~ 70 is required . Patients who have
received prior radiation therapy to the
brain or who need immediate treatment
to prevent neurological deterioration are
ineligible for the study.

retrospectively studying the genetic
profiles of patients in an attempt to
find a link between genes and clinical
outcome.
"We're going to study an individual
patient's tissue to study their genestheir makeup--and then compare it to
their clinical outcome on the various
therapies," Dr. Amato said. "Eventually,
the study will be prospective once we
are able to gain the necessary data
from it to develop diagnostic and
therapeutic applications."
For the past year, the number
of patients receiving treatment
through the renal cell program at
M. D. Anderson has been growing

each month, with the GU Center
patients with renal cancer outnumbered only by those with prostate
cancer.
"The program is attracting
patients because we have a lot of
therapy options and because we're
experts in the care of renal cancer,"
said Dr. Amato. Another reason
patients come to M. D. Anderson,
according to Dr. Amato, is because
the Kidney Cancer Association, a
patient organization whose h eadquarters are in Chicago, selected
M. D. Anderson as the preferred
care center for renal cell carcinoma
in its region.

The statistics explain why
more effective treatments
for renal cell carcinoma
are desperately needed.
Dr. Amato, who has worked in
genitourinary oncology at M. D.
Anderson since he completed his
fellowship at the institution 11 year
ago, is the principal investigator
in some M. D. Anderson trial
whose aims are to exploit r nal II
carcinoma's immune re pon iv n
(Continued on page 4 )

- - - - :- PROTOCOLS --:- -Other protocols for patients with renal
cell carcinoma include the following:
• Phase 11 clinical study of liposomeentrapped cis-bis-neodecanoatotrans-R, R-1,2-diaminocyclohexane
platinum (II) in patients with renal
cell carcinoma (DM98-197). Physician:
Lori Wood, M.D. Eligible for this
protocol are patients with disease
metastatic to the kidney who have had
one or two courses of immunotherapy
or chemotherapy.
• Phase 1/11 clinical trial of weekly intravenous Onconase plus daily oral 13-cisretinoic acid and subcutaneous interferon-alpha in patients with metastatic
renal cell carcinoma (DM98-335).
Physician: Lori Wood, M.D. Patients
with metastatic renal cell carcinoma
are eligible for enrollment.

I

• Phase 11 study of interleukin-2, alphainterferon, and granulocyte-macrophage
colony-stimulating factor in patients
with metastatic renal cell carcinoma
(DM98-139). Physician: Robert Amato,
D.O. Patients who have not had any
prior therapy and who may or may
not have undergone nephrectomy
are eligible.

• Phase I study of temozolomide in
patients with metastatic renal cell
carcinoma (DM98-116). Physician:
Lori Wood, M.D. Eligible are patients
who have had any prior chemotherapy
and/or immunotherapy.
• Phase II study of capcitabine for patients
with metastatic renal cell carcinoma
(DM98-226). Physician: Lori Wood,
M.D. Patients who have had one prior
course of immunotherapy are eligible.
• Phase II study of MGl-114 administered
intravenously for five days every 28 days
to patients with metastatic renal cell
carcinoma (DM98-221 ). Physician:
Robert Amato, D.O. Patients who have
had one prior course of immunotherapy
may enroll.
• Thalidomide for interleukin-2 progressing patients with metastatic renal cell
carcinoma (I099-019). Physician:
Robert Amato, D.O. Eligible are patients
who have undergone one or two
treatment regimens with interleukin-2.
• Phase 1/11 study of interferon-alpha 2b,
doxorubicin, and ifosfamide for patients
with metastatic sarcomatoid carcinoma
of the kidney (DM96-291 ). Physician:

Robert Amato, D.O. To be eligible for
enrollment, patients must have uncommon histology-sarcomatoid carcinoma
of the kidney.
• Phase II study of 5-fluorouracil, interferon-alpha 2b, and cisplatin for
patients with metastatic or unresectable
collecting duct carcinoma of the kidney
(DM97-015) . Physician: Robert Amato,
D.O. To be eligible for enrollment,
patients must have uncommon histology-collecting duct carcinoma of
the kidney.
• Evaluation of pain control and quality of
life in patients with metastatic renal cell
carcinoma (DM96-307) . Physician:
Robert Amato, D.O. All patients with
metastatic renal cell cancer are eligible
for enrollment.
about these clinical
trials, physicians or patients ma call the
M. D. Anderson Information Line. Tho e
within the United States, call ( 00) 3921611; those in Houston or outsid-e the
United States, call (713) 792-6161.
Visit the M. D. Anderson Cancer Center
clinical trials Web site at http:/ I
www.clinicaltrials.org for a broader
listing of treatment research protocols. •

FoR MORE INFORMATION
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New Options Expand Renal
Cancer Therapy Program
(Continued from page 3)

In one of these, patients with
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New Quarterly Supplement Offers
Perspedives on Clinical Guidelines

W

ithin this Oncolog, readers will discover the premier issue of
Compass, a quarterly four-page pull-out supplement offering
perspectives on clinical guidelines developed by multidisciplinary
teams at M. D. Anderson. These guidelines are also available on
the Cancer Manager Web site-http://www.cancermanager.org. Each quarterly
issue will contain a different clinical practice guideline prepared by a different
group. On the Web, readers will find an expanded version that provides continuing medical education category 1 credit for successful completion of testing.
The multidisciplinary faculty team that developed the invasive breast cancer
guideline is represented in this issue by Richard L. Theriault, D.O., associate
professor of medicine; S. Eva Singletary, M.D., chief of the Surgical Breast
Service and professor of surgery in the Department of Surgical Oncology; and
Marsha D. McNeese, M.D., chief of the Breast Radiotherapy Service and associate professor of radiation oncology in the Department of Radiation Oncology.
Not intended to be prescriptive, the guidelines are recommendations provided
within a framework that is meant to be useful to physicians as they make care
choices relying on their own best judgment. The text that accompanies the
charts should help interpret decisions reflected in them.
Upcoming issues this year are expected to focus on clinical practice guidelines
for prostate, colorectal, and lung cancer. •

85% of all renal cell carcinomas.
C225, a chimeric monoclonal antibody, specifically binds EGFr, blocks
activation of the receptor tyrosine
kinase, and inhibits tumor growth
in preclinical models.
More than 27% of the 54 patients
enrolled in the study showed a
biologic response to the eight weekly
intravenous infusions, and no serious
side effects were seen. A phase I and
II study of C225 in combination with
interleukin-2 is planned for this
summer.
"Many of those clinical trials also
have complementary laboratory
participation from scientists at M. D.
Anderson," Dr. Amato added.
Other areas of research in the
treatment of renal cancer include

a pilot study of thalidomide used as
an angiogenesis inhibitor; phase I
and II immunotherapy trials of
interleukin-2, alpha-interferon, and
granulocyte-macrophage colonystimulating factor; several trials of
capcitabine, temozolomide, MGI-11 4,
and a combination of Onconase,
13-cRA, and interferon; a phase II
study of liposome-entrapped cisbis-neodecanoato-trans-R, R-1 ,2
diaminocyclohexane platinum (II);
and two trials of chemotherapy
combinations for patients with
metastatic sarcomatoid carcinoma
and metastatic or unresectable
collecting duct carcinoma. •
FoR MORE INFORMATION,

at (713) 792-2830.

contact Dr. Amato
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CLINICAL
DISCUSSION:
Invasive Breast
Cancer
About These Clinical
Practice Guidelines
This guideline may assist in the
diagnostic evaluation of patients with
clinical symptoms or positive screening
tests (if such testing exists). The clinician is expected to use independent
medical judgement in the context of
individual clinical circumstances to
determine any patient's care.
M . D. Anderson Cancer Center's
Practice Guidelines are con tinuously
updated as n ew information becomes
available and are n ow being expanded
to inclu de the entire spectrum of cancer
man agement. New Guidelines for
Screening and Diagnosis are currently
under development. The most current
version of all M. D. Anderson Practice
Guidelines can be found on the World
Wide Web at http:/I
www. cancermanager.

SPRING 1999, VOL 1, NO. 1

Richard L Theriault,
D.O.
Medical Director,
M. D. Anderson
Physicians' Network
Associate Professor
of Medicine
Department of Breast Medical
Oncology
S. Eva Singletary, M.D.
Chief, Surgical
Breast Service
Professor of Surgery
Department of Surgical
Oncology
Marsha D. McNeese,
M.D.
Chief, Breast
Radio therapy
Service
Associate Professor of
Radiatio n Oncology
Department of
Radiation Oncology

Scope of this Guideline
This guideline addresses treatment decisions for stages I-IV
invasive breast cancer. The algorithm begins with the diagnosis
having been established and staged
clinically according to TNM classifications. Noninvasive breast cancers
(stage 0-Tis NO MO) are addressed
in a separate guideline, as are
screening and diagnosis. These and
Practice Guidelines for other types
of cancer are currently available
on the website.
Continuing Medical Education:

An expanded version of these
materials with CME category 1
credit is available on the internet at
http://www.cancermanager.org

Synopsis & Highlights
Initial workup for all stages includes
standard preoperative evaluations
plus studies aimed at sites most likely
to show evidence of metastasis (liver,
bone, lung) . Note that clinical staging
may change after this evaluation and
at other points in the process where
new information is gained.

Treatment for invasive breast cancers
includes treatment of local disease
with surgery, radiotherapy, or both
and treatment of systemic disease
with chemotherapy, hormone
therapy, or both.

Surgery
Based on the results of a number
of large randomized trials, experts
agree that total mastectomy and
segmental mastectomy (lumpectomy)
followed by radiation are medically
equivalent options, according to Dr.
Singletary. Currently, axillary node
dissection is done in both cases.
Breast-conserving surgery followed
by radiation is an option in cases
where:
a) negative margins can be obtained: Total mastectomy must
be offered in cases where this is
not possible because of tumor
size, multicentricity, or other
anatomic considerations.
b) there is no contraindication to
radiotherapy: Patients in whom
radioth erapy is contraindicated
are treated with total m as tectomy. Contraindicatio ns include
p revious radia tion to the ch est
area, some collagen vascular and
(Continued on next page)

Breast Cancer (Invasive)*
CLINICAL
STAGE

INITIAL
EVALUATION

Q

Note: If available, clinical trials should be considered
as preferred treatment options for eligible patients.
Segmental mastectomy
(preferred over total
mastectomy) with
axillary node dissection

CBC, platelets, liver
function tests (total
bilirubin , alkaline
phosphatase,
SGPT, LDH)

Node negative and tumor <1 cm;
consider other prognostic factors 1 - - - . . i No systemic treatment

Radiotherapy prior
to or after systemic
chemotherapy

Pathology review**

Stage I

T1 NO MO
or

Stage IJA
TO N1 MO
T1 N1 MO
T2 NO MO
or
Stage 116

T2 N1 MO
T3 NOMO

SURVEILLANCE

SYSTEMIC TREATMENT

LOCAL TREATMENT

CXR
Bilateral diagnostic
mammography
Bone scan if;
- Stage t and signs
or symptoms or
- Stage HA or 118
CT of abdomen or
US of liver if:
- Stage I and signs
or symptoms or
- Stage IIA or 118
EKG if >60 yr
Estrogen and progesterone receptors
Her-2neu

1-3 positive
nodes

• Paclitaxel followed
by FAC or
e AC followed by
paclitaxel

4ormore
positive nodes

• Paclitaxel followed
by FAG or
e AC followed by
paclitaxel or
e A-CMF

Radiotherapy prior
to or after systemic
chemotherapy
Node negative

----IM---..-i

<1 o positive nodes:
see Post Mastectomy
Irradiation notes on website
at www.cancermanager. org

Physical exam every
4 mo for 2 yr; every
6 mo for 3 yr; then
yearly.
Mammography yearly.
CXR for XRT patients
yearly.
Women on tamoxifen:
pelvic exam yearly.
If adjuvant chemotherapy, CBC,
differential, platelets,
alkaline phosphatase,
SGPT, and LDH
yearly.

< 1Opositive nodes
• Paclitaxel followed
or tu mor ;?:5 cm or
by FAG or
margins positive or - - - - - - - - - - - , ~ • AC followed by
extensive lymphatic
paclitaxel or
_.,
invasion
• A-CMF

______

*There are special circumstances in which these guidelines do not apply.
These include, but are not limited to:
- Sarcoma and lymphoma of the breast
- Special histologies (i.e., tubular, medullary, pure papillary, or colloid)
- Patients with gross multicentricity or diffuse microcalcifications
- Patients with lupus, scleroderma, and possibly other collagen
vascular disorders
- Patients with limited life expectancy because of comorbid illness
- Cancer during pregnancy

**Pathology review to include:
-Tumor size
- Differentiation
- Nuclear grade
- Histologic type
- Lymph node status
- lntramammary vascular/lymphatic invasion

I..J

Radiotherapy
after systemic
chemotherapy

AC = Doxorubicin and cyclophosphamide
A-CMF = Doxorubicin with cyclophosphamide, methotrexate, and fluorouracil
FAG = Fluorouracil, doxorubicin , and cyclophosphamide

Breast Cancer (Invasive)

Q

WORKUP

CLINICAL
STAGE

Treatment

Note: If available, clinical trials should be considered as preferred treatment options for eligible patients.

CBC, platelets, liver
function tests (total
bilirubin, alkaline
phosphatase,
SGPT, LDH)
Pathology review*
EKG if >60 yr

Total r:nastectomy
with axillary node
dissection (MAM)
with/without
reconstruction

Tumor;?:1 cm
and 1-3 positive
nodes

Treatment

SURVEILLANCE/
FOLLOW-UP

LOCAL AND SYSTEMIC TREATMENT

• Paclitaxel followed by
FACor
• AC followed by
pacHtaxel

CXR

,__ _ _ Bilateral diagnostic
mammography
Bone scan
CT of abdomen or
ultrasound of liver
Estrogen and progesterone receptors
Her-2neu
~

1-----

Inoperable

(N2, some T3)

• Paclitaxel followed by
FACor
e AC followed by
paclitaxel or
• A-CMF

Physical exam every
4 mo for 2 yr; then
every 6 mo for 3 yr;
then yearly.
Mammography yearly.

· silver
function

r.YA f/"\r r,:irli/"\thor,:i ~

ifs (fata l

patients annually .

bflirubln, H allne
phosphatase,
SGPT, LDH)
Pathology review*
EKG if >60 yr

CXR
Bilateral diagnostic
mammography
Bone scan
CT of abdomen or
US of liver
Estrogen and progesterone receptors
Her-2neu

*Pathology review to include:
- Tumor size
- Differentiation
- Nuclear grade
- Histologic type
- Lymph node status
- lntramammary vascular/lymphatic invasion

No

Radiotherapy

pelvic exam yearly.
If adjuvant chemotherapy, CBC ,
differential, platelets,
alkaline phosphatase,
SGPT, and LOH
yearly.

AC = Doxorubicin and cyclophosphamide
A-CMF = Doxorubicin with cyclophosphamide , methotrexate, and fluorouracil
FAG= Fluorouracil , doxorubicin , and cyclophosphamide

Ver:Compass/1 /1/#2

EVALUATION
FOR RECURRENCE
OR METASTASIS

□ Treatment
TREATMENT FOR RECURRENCE OR METASTASIS
Note: If available, clinical trials should be considered as preferred treatment options for eligible patients.

Consider segmental mastectomy
and radiotherapy
Total mastectomy
Consider wide local excision
CBC, differential, platelets,
liver function tests (total
bilirubin, alkaline phosphatase, SGPT, LDH)

Neoadjuvant
systemic therapy

Bone scan
CT of abdomen or ultrasound
if signs or symptoms
Imaging of symptomatic
areas
Biopsy documentation of
first recurrence , if possible
Estrogen and progesterone
receptors, if possible

Nonresectable
Resectable

CXR

,-..,
N-eo-a-,
dj-,
uv-a-nt~

Distant
metastasis

ER positive and
symptomatic visceral; or
ER and PR negative; or
symptomatic visceral
Surgery, radiation therapy and regional chemotherapy may be indicated
for localized clinical scenarios:
8. Impending pathologic fracture
1. Brain metastases
9. Pathologic fracture
2. Leptomeningeal disease
10. Cord compression
3. Choroid metastases
11 . Painful lesions
4. Pleural effusion
12. Plexopathy/ radiculopathy
5. Pericardia! effusion
13. Superior vena cava syndrome
6. Biliary obstruction
14. Extensive locoregional disease
7. Ureteral obstruction

►

(

Surgical resection )

Nonresectable

systemic therapy

ER and/or PR positive and
bone or soft tissue only or
ER and/or PR positive and
asymptomatic visceral

systemic
th:'.:8:'.;
' 8'.!:P!,
Y_

J---------.'\,,'.'.

_..._~

~

Consider individualized
systemic therapy

t~~cf:i[:n+

Tamoxifen

Additional hormone therapy:
1. Aromatase inhibitors if post•
menopausal or
LHAH agonist/antagonist if
premenopausal
2. Megestrol acetate
3. Androgens
Chemotherapy until progressive disease:
1. Fluorouracil, doxorubicin, and cyclophosphamide
2. Paclitaxel or docetaxel
3. Navelbine
4. Capecitabine
Note: Herceptin may be used for Her-2neu positive
patients; not to be used with doxorubicin.
*See additional chemotherapy options below
*Additional chemotherapy options: 1. MTXNlb
2. Mitomycin C
3. Mitoxantrone

Continue tamoxifen until progressive
disease then consider other hormone
therapy as listed in additional hormone
therapy box (to left)

Failure to respond to 2
sequential regimens or
Zubrod status ;?:3,
discontinue chemotherapy

Radiotherapy
According to Dr. McNeese, for
patients with intact breast (segmental resection), radiotherapy is
delivered to the breast alone if
the patient had stage I or II disease
unless 4 or more axillary nodes
were involved or extranodal extension greater than 2 mm is seen.
In the postmastectomy setting,
patients who are considered to be at
significant risk for local recurrence
should receive radiation treatment
in the postoperative setting rather
than waiting for recurrence. Risk is
currently assessed primarily by stage
and number of involved lymph
nodes. Most clinicians agree that
patients with stage III breast cancer
and patients with 10 or more
involved lymph nodes are at substantial risk for local recurrence
and should ~" :~~:·:~ i,,21_1.:li::ition.
cancer and three or fewer diseased
nodes would be at low risk and less
likely to benefit. For those who
fall between these parameters ( 4-9
nodes), the data from numerous
studies are unclear.

Individualize any further treatment

Breast Cancer (Invasive)

Another important variable is
patient preference. It is not uncommon for a patient to choose total
mastectomy over breast conservation. The recommended approach
is to ensure that the patient is aware
of the options and to assist her in
feeling secure with her choices
about the management of her
cancer.
When total mastectomy is required or chosen, the possibilities
and preferences for reconstruction,
whether immediate or delayed,
should be part of the dialogue and
of the plan, as they will influence
the surgeon's actions.

while patien---, with stage l or 11

Women on tamoxlten:

• Total mastectomy with
axillary node dissection
(MRM)or
• Segmental mastectomy
with axillary node
dissection

(Continued from previous page)
immune· disorders, pregnancy,
comorbid conditions that preclude patients from coming for
daily treatment, or patient
preference.

_)

Chemotherapy
Systemic cytotoxic chemotherapy
should be considered in the adjuvant setting for all patients whose
tumor is larger than 1 cm, in all
patients who have disease positive
nodes, and in patients where other
prognostic indicators are of concern
(angiolymphatic invasion, high Sphase fraction, high nuclear grade,
or high histologic grade), according
to Dr. Theriault.
Chemotherapy is used in the
neoadjuvant setting in stage IV or
inoperable stage III breast cancers,
with the goal of downstaging disease
or rendering tumors operable.
Chemotherapy is also used to treat
local disease recurrence to attempt
to reduce risk of distant metastasis.
In the setting of distant recurrence
(metastasis), chemotherapy is used
in hormone receptor-negative
tumors, in cases nonresponsive to
hormone therapy, and where there
is symptomatic visceral metastasis.
In this setting, the chosen regimen
is continued until disease progresses.
As there are a variety of appropriate
chemotherapy combinations, this
line of therapy is discontinued in
favor of palliative care only after
failure of response to two sequential
regimens or when Zubrod status
2':_ 3 is reached.
Hormone Therapy
Tamoxifen is currently considered
the preferred first-line hormonal
(Continued on next page)

f>('. trt'\ CTPn

receOtOr

till

Surveillance & follow-up: Posttherapy follow-up care includes
regular physical exams and yearly
mammography for all patients.
Chest x-rays are indicated yearly for
patients who have had radiotherapy.
Women treated with tamoxifen
should have a yearly pelvic exam
and rapid evaluation of reported
vaginal spotting.
Patients who have had cytotoxic
chemotherapy should also have yearly
CBC, differential, platelets, alkaline
phosphatase, SGPT, and LDH.

Authors' Perspedives ...
Sequencing local and systemic treatment,
according to Dr. Theriault, is the
greatest challenge. While the
decision points reflected in guidelines seem sequential - surgery
first, followed by radiation, chemotherapy or both - the treatment
plan for an individual patient
requires dynamic interaction.
"Cancer is not an emergency," says
Theriault, urging clinicians not to
rush to treatment and emphasizing
the importance of clinical assessment and strategic planning. It is
not uncommon to see women who
have undergone mastectomy but
would have derived more benefit
from chemotherapy as an initial
treatment or who are ineligible for
certain therapies because of ante-
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peutiC sequence can be achieved.
Consider biopsy as the first step in
treatment, and approach any suspicious
lesion as if it is cancer, advises Dr.
Singletary. The technique used
for biopsy can have considerable
consequences for future diagnostic,
treatment, and reconstruction
options. Large biopsy scars, failure
to achieve and document clear
margins, and tunneling for peripheral tumors are concerns that may
limit subsequent options for surgical resection, radiotherapy, and
reconstruction. In addition, techniques that distort breast tissue in
any way may obscure key diagnostic
and staging parameters. Dr.
Singletary's general recommendations are that where possible, an
expertly performed needle biopsy
is preferable to a surgical biopsy
because it leaves more options open
for future treatment, that all surgical specimens should be carefully
documented and inked for margins,
and that it is preferable for the
surgeon to confer in person with
the pathologist on specimens.
Think about clinical trials as a first
resort. According to all of our
experts, while it is not uncommon
to think about clinical trials at end
stage disease, enrollment in proto-

urrenc
many studies involve investigation
of new treatment regimens, there
are also protocols which address
"softer" clinical issues such as
coping and support mechanisms,
techniques for enhancing well-being
and quality of life, and management
of pain and other cancer-related
symptoms such as fatigue.
'-J

It is not uncommon to encounter
misconceptions related to research,
so it may be useful to help patients
and their families understand that
in clinical trials at a reputable
institution, patients do not receive
less than the standard of care treatment, nor should they be required
to give up their relationship with
their own physician when they
enroll in a protocol.
When possible, it is a good idea
to research available clinical trials
and contact the principal investigator before initiating therapy, as
some antecedent treatments may
disqualify a patient as a candidate
for potentially beneficial treatments
and trials.
Listings of current protocols
available at M. D. Anderson can be
found on the World Wide Web at
http: / / www.cancermanager.org or
by contacting the M. D. Anderson
Information Line at 1-800-3921611 / option 3.
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Individuals should not rely exclusively on information
contained in these clinical guidelines. Health care
providers must use their own professional judgment in
treating patients. Individuals should not substitute
these guidelines for professional medical advice,
diagnosis, or treatment and should consult a qualified
physician if they have medical questions or concerns.
The University of Texas M. D. Anderson Cancer
Center makes no warranties or representatians,
expressed or implied, as w the accuracy, completeness, or usefulness of the information contained or
referenced in the clinical guidelines and disclaims
any and all liability for injury and/or other damages
to any third party resultingfrom any individual's
followi,ng these guidelines.
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Alcohol and Cancer: Making Sense
of a Cocktail of Risks and Benefits
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or After Systemic TherapyThat Is the Question
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Center. He hopes to enroll
144, the number needed to
show whether nephrectomy
or biologic therapy should
be initiated first.
"Basically, the reason
it took so long to develop
this protocol is because it
is an emotional issue," Dr.
Wood said. "Some people
feel strongly about it one
way or the other.
"If you have a patient
who comes to you with
asymptomatic metastatic
disease, the question in
your mind is, Is there a
benefit to removing the
kidney? Do I think that the
patient's metastatic tumors
might respond better if!
remove the kidney? The
alternative plan of action
is to give patients systemic therapy,
see if they respond, then go back and
take out the kidney and take out any
residual metastatic sites," Dr. Wood
said. "There's actually a good argument for giving them systemic
therapy first, because if they don't
respond to the systemic therapy, then
you clearly wouldn't subject them
to a surgical procedure. In that
instance, you may save some people
from unnecessary surgery. This
protocol is going to answer these
questions for us so we can intelligently apply surgery in the
face of metastatic disease."
At M. D. Anderson, initial nephrectomy is a standard component of
several clinical protocols for metastatic renal cell carcinoma. The
surgery can be safely performed
but requires very careful patient
selection, especially attentive
perioperative care, and expeditious
referral for systemic therapy.
Dr. Wood said that several studies
have looked retrospectively at the
number of patients who have gone

"This protocol is going to
answer ... questions for
us so we can intelligently
apply surgery in the face
of metastatic disease:'
- Christopher G. Wood, M.D.
Assistant Professor, Department of Urology
on to receive systemic therapy
after kidney removal.
"Here at M. D. Anderson, it's
actually quite good. It's 94%," he
said. "In some published reports, it's
as low as 50% or 40%," he reported,
adding that experience accounts for
M. D. Anderson's ability to help
patients over the hurdle of nephrectomy and on to systemic therapy.
Such major operations as nephrectomy carry the risk of postoperative
complications that at minimum can
postpone the beginning of therapy or
at worst put the patient's life at risk.
Also, after undergoing nephrectomy,

patients must wait about four weeks
to allow their wounds to heal before
beginning systemic therapy. During
that time, any metastases that remain
go untreated and may continue
to grow. Reducing the chance of
significant complications that can
prevent or postpone pursuit of other
therapy options requires skill.
For patients who go on to systemic
therapy, Dr. Wood said that M. D.
Anderson researchers have several
novel protocols under way. He said
the effort "basically amounts to a
series of phase I and phase II protocols delivering experimental therapy
with the recognition that the current
therapy for metastatic renal carcinoma is woefully inadequate."
Standard immunotherapy for
metastatic renal cell carcinoma
administered at M. D. Anderson is
a three-drug regimen that includes
interleukin-2 with interferon-alpha
and 5-fluorouracil. Response rates
range between 35% and 40%, but
disease tends to recur fairly quickly.
The percentage of complete responses is only about 5% to 6%.
Dr. Wood lays part of the blame
for the poor performance of stateof-the-art therapy on the lack of
research being conducted on kidney
cancer. Because it is less common
than some other forms of cancer,
it is more difficult to get funding
for research, he said. "If you have
no research, it's hard to make
incremental advances," he explained.
Among those trying to change
that, Dr. Wood said, is the National
Kidney Cancer Association, which is
making strides to increase awareness
of kidney cancer and funding for
research. The group was founded by
the late Eugene P. Schonfeld, Ph.D.,
who had kidney cancer. When he was
a resident at Northwestern University,
Dr. Wood met Dr. Schonfeld. The
association encourages research by
providing money and information to
help researchers in academic medical
centers, government, and industry. It
is also a source of information about
kidney cancer to physicians, patients,
and their families. "It is trying to get
the word out," Dr. Wood said. •
FoR MORE INFORMATION,

at (713) 792-3250.

contact Dr. Wood

Training Takes Prevention
R:~rly De{;ion ~W~rldwitle
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ever had a screening mammogram? If you live in Japan,
that's typical.

"Women get their first mammogram only after they discover a breast
lump," says Miyu Nakamura, nursing professor at the Hamamatsu U niversity
School of Medicine in Hamamatsu-shi,Japan.
Helping health professionals rethink that kind of limited use is exactly what
the Professional Education Program for Early Detection (PEPED) tries to do.
Miyu Nakamura and another nurse, Harne Nakamura (the two are unrelat d),
recently traveled to Houston to complete a PEPED cancer prevention profe ional
education program at The University of Texas M. D. Anderson Cancer Cent r.
PEPED trains health care professionals from around the wo rld about th
most advanced screening and early detection methods for breast, gynecologi ,
genitourinary, colorectal, skin, and head and neck cance rs. The newe t
module is genetic counseling. "This type of training for m edical pro£ ion al
is needed," says PEPED director Jane Williams, M.S.N. , F.N.P., "becau t
many cancers remain undiagnosed until dise~e progresses to a lat tag .".
Since its inception in 1975, PEPED has tramed more than 20,000 m d1 a l
professionals from the United States and many foreign coun trie . L!nda
White Hilton, clinical administrative director of the Can cer Prevenll n
Center, helped found the program, which was one of the fi rst in the nati n t
pair clinical experience with classroom teaching in scree ning. J. Taylor
Wharton, M.D., was its medical director.
PEPED offers short-term intensive education courses for health car
professionals, already proficient in their fields , who wan t to implem nt n _,.
cancer detection programs in hospitals or physician offices, or update XI on
programs. Certification follows successful completio n of PEPED cou
..
The nurses, who learned about PEPED from an M. D. Ander on-tram d
Japanese physician, were the first health care professional fro m Japan t
complete PEPED training.
"We wanted very much to learn to detect cancer at an early tag for
our patients," Miyu Nakamura says. •
FOR MORE INFORMATION

about PEPED, call (713) 792-3457.

Instructor Patricia Ewert-Flanagan, R.N., M.S.N.,
0.C.N., (right) teaches Harue Nakamura (left) and
Miyu Nakamura breast cancer detection techniques.
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Thirteen-story Alkek Hospital Makes Debut
.

T

he new 13-story Albert B. and
Margaret M. Alkek Hospital,
an expansion of The
University of Texas M. D.
Anderson Cancer Center, has opened
on the Texas Medical Center campus
in Houston. The building provides 198
beds for inpatient care and 26 .new
surgical suites. Included is new room
for diagnostic imaging, perioperative
patient care, intraoperative and other
radiation treatment, pathology and
pharmacy surgical support, and rehabilitation services. Inpatient units serve
pediatric and adolescent patients,
medical-surgical patients, and hematology
patients.
Additional space within the building,
which is located west of the Clark Clinic,
8 I MD Anderson OncoLog

1!('1

is expected to be devoted to more
inpatient care.
Architects brought the outdoors in on
the Alkek Hospital's second floor, where
trees, shrubs, flowers, and a fountain
offer respite to patients and visitors. A
flower and gift shop sells items to meet
needs and brighten spirits, and M. D.
Anderson's history is told in the John P.
McGovern, M.D., Visitors Gallery, a
2, 700-square-foot exhibit space.
The new hospital, part of an overall
modernization, follows erection of new
facilities for outpatients and basic research, the Charles A. LeMaistre Clinic
and the Clinical Research Building.
The Alkeks initiated the effort for a
new hospital in 1993 with a gift of
$30 million. •
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